UPDATE ‐‐ China Medical Equipment & Technical Service Co. (Meheco) Named the Exclusive Partner for Miramar Labs’® miraDry® Distribution in China

SANTA CLARA, Calif., — June 17, 2016 — Miramar Labs, Inc., (OTCQB: MRLB), a global aesthetic company announced today that it has entered into an exclusive distribution agreement with Meheco, a state-holding company listed on the Shanghai Stock Exchange (Ticker Symbol: China Meheco; Stock Code: 600056). Miramar Labs received the China Food and Drug Administration (CFDA) initial approval in May 2015 for the marketing and sale of miraDry® system in the People’s Republic of China and full approval to distribute its product in April 2016. The miraDry® system utilizes the Company’s proprietary miraWave® technology and is the first non- surgical system to permanently eliminate apocrine and eccrine glands in the axilla which are the cause of unwanted sweat and odor.

Meheco is dedicated to the promotion of human health and has been offering excellent service to global customers for over 30 years. It has established strategic partnerships with numerous well-known transnational medical device companies.

This represents a significant market expansion opportunity for Miramar Labs and the miraDry® system and will supplement sales for miraDry® in over 40 countries.

Mike Kleine, President and Chief Executive Officer of Miramar Labs said, “This partnership with Meheco is a significant advancement in our worldwide distribution efforts, as well as in creating new markets for axillary sweat and odor reduction. Meheco’s commitment to this venture is firmly demonstrated through their establishment of a sales and support team solely dedicated to miraDry®. We couldn’t be more pleased with the partnership”.

Sales VP for Meheco added, “We are very pleased and excited about our new partnership with Miramar Labs. This has been an untouched market with a large population suffering from excessive underarm sweat and odor. We strongly believe Miramar Labs’ unique miraDry® technology offers significant opportunities by delivering new innovative applications to treat unmet needs in China’s rapidly growing aesthetic market”.

About Miramar Labs:

Founded in 2006, Miramar Labs, Inc., is a global medical device company dedicated to bringing innovative applications to treat unmet needs in the aesthetic marketplace. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company’s first priority is the treatment of bothersome underarm sweat, an issue that millions of people deal with daily. The miraDry® procedure has an established safety and efficacy profile with over 55,000 patients treated worldwide. Physicians and patients are encouraged to visit www.miramarlabs.com or www.miradry.com for additional information.

Contact:
Investors:
Brigid Makes
Sr. Vice President & CFO
Phone: 408.579.8700
Email: investors@miramarlabs.com

Media/Other:
Robert Ellis
Vice President of Global Marketing
Miramar Labs
Phone: 408-579-8706
Email: info@miramarlabs.com

Miramar Labs, Inc. Completes Alternative Public Offering, Raises $9.0 Million

Funding to Support Further Commercialization of miraDry® for Sweat Reduction and Innovation of New Products

SANTA CLARA — June 8, 2016 — Miramar Labs, Inc. (OTCQB: KTLC), announced today its successful completion of a reverse merger with Miramar Technologies, Inc., the manufacturers of the miraDry® system which delivers microwave energy to non-invasively destroy sweat and odor glands in the underarm. The combined entity will trade on the OTC Markets solely focusing on the business of Miramar and has applied for the ticker symbol “MIRA”.

Miramar also announced today that it has completed a private placement with gross proceeds of approximately $9.0 million from the issuance and sale of 1.8 million shares of its common stock. Proceeds from the private placement will be used to support the ongoing commercialization of the miraDry® system, for the development and clinical studies related to products targeted for new indications, and for general corporate purposes, including working capital. Investors in the private placement included Domain Associates, Morgenthaler Partners, Aisling Capital, RusnanoMedInvest (RMI), Cross Creek Advisors, and Montrose Capital Partners.

“The financing, in connection with Miramar’s alternative public offering, will provide resources necessary to continue our delivery of new innovative applications to treat unmet needs in the aesthetic marketplace,” said Michael Kleine, Miramar’s CEO. With over 55,000 patients already treated with the miraDry® procedure in over 40 countries, we have firmly established that microwave technology is not only an acceptable treatment option, but it has become the treatment of choice in physician’s offices for the reduction of underarm sweat.”

In connection with the private placement, Miramar has agreed, subject to certain terms and conditions, to file a registration statement under the Securities Act of 1933, as amended, covering the resale of the shares of common stock issued in the reverse merger and the private placement and in connection with the exercise of warrants issued to the placement agents, within 90 days after the closing. The shares of common stock issued or to be issued pursuant to the merger, the private placement and the placement agent warrants have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Miramar Labs:
Founded in 2006, Miramar Labs is a global medical device company dedicated to bringing innovative applications to treat unmet needs in the aesthetic marketplace. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company’s first priority is the treatment of bothersome underarm sweat, an issue that millions of people deal with daily. The miraDry® procedure has an established safety and efficacy profile with over 55,000 patients treated worldwide. Physicians and patients are encouraged to visit www.miramarlabs.com or www.miradry.com for additional information.

Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Miramar’s technologies, anticipated uses of proceeds from the private placement, business and product development plans, physician adoption and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Miramar’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the miraDry® system, competition in the industry in which Miramar operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and Miramar assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should review all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Miramar files with the SEC, available at www.sec.gov.

Contact:
Investors:
Brigid Makes
Sr. Vice President & CFO
Phone: 408.579.8700
Email: investors@miramarlabs.com

Media/Other:
Robert Ellis
Vice President of Global Marketing
Miramar Labs
Phone: 408-579-8706
Email: info@miramarlabs.com

Miramar Labs® Announces New Optimized Treatment Protocol to Increase miraDry® Patient Volume and Satisfaction

SANTA CLARA, Calif., July 30, 2015. Miramar® Labs, a global aesthetics company, today announced the release of the Optimized Treatment Protocol (OTP) in Europe and the Middle East. The new protocol, designed to increase patient satisfaction and reduce treatment times, should further expand the potential patient population for the miraDry® System which eliminates underarm sweat and odor glands.

The miraDry System received CE Mark approval in December 2013 following US FDA clearance in January 2011. The Optimized Treatment Protocol is the ideal approach for improving the miraDry value proposition for both physicians and patients. OTP continues to build upon a procedure with one of the highest efficacy and patient satisfaction records among aesthetic treatments.

“The new OTP has made a significant difference in my miraDry business,” said Dr. Grant Stevens of Marina Plastic Surgery in Marina Del Rey, Calif. “In the short time since I started using the new protocol my patient volume has more than doubled and continues to grow. The treatment is ideally suited for my cosmetic patients and the new protocol has enhanced the treatment in such a way that I feel compelled to tell every patient about it. With permanent benefits and minimal downtime, there is no better solution for treating unwanted underarm sweat.” Dr. Stevens is also clinical professor of surgery at the University of Southern California.

Miramar Lab’s proprietary miraWave® technology –use of precisely controlled microwave energy – is the foundation of the miraDry System. It is a significant technological advancement in the aesthetic market. The miraDry system is currently distributed in over forty [40] countries worldwide. The company reports over 40,000 miraDry treatments, and sweat reduction is one of the fastest growing segments in aesthetics.

For more details on the Optimized Treatment Protocol click here for a live recording of the recent OTP Webinar.

About Miramar Labs:
Founded in 2006, Miramar Labs is a privately owned global medical device company dedicated to bringing the next generation energy modality to the field of dermatology. Supported by rigorous clinical research, Miramar Labs is focused on addressing aesthetic medical conditions for which there are significant unmet clinical needs. The company’s first priority is advancing aesthetic treatments using its proprietary miraWave technology. Physicians and patients are encouraged to visit www.miramarlabs.com for additional information about Miramar Labs.

Contact:
Elisabeth Barbaria
Sr. Marketing Manager
Miramar Labs, Inc.
Ph: 408.579.8774
E: ebarbaria@miramarlabs.com

Miramar Labs® Announces FDA Clearance for the permanent reduction of underarm hair of all colors and subsequent launch of miraSmooth™

SANTA CLARA, Calif., July 23, 2015. Miramar® Labs, an innovative global aesthetic company, announced today its miraDry® System received clearance from the U.S. Food & Drug Administration (FDA) for the treatment of unwanted underarm hair, and permanent reduction of underarm hair of all colors. This announcement establishes miraDry as the only technology FDA cleared for the treatment of underarm hair of all colors as well as the permanent reduction of underarm sweat.

“This approval further validates Miramar’s unique technology in creating and addressing aesthetic markets that could not be fully satisfied with other energy platforms”, commented Mr. Michael Kleine, CEO and President of Miramar Labs. According to Mr. Kleine, “We believe the potential for microwave energy in aesthetics is exceptional. Miramar was the first company to receive clearance for axillary sweat reduction and we are now the only company with FDA clearance for permanent reduction of axillary hair of all colors. These are both tremendous market making opportunities in aesthetics.”

Miramar Lab’s proprietary miraWave® technology – use of precisely controlled microwave energy – is the foundation of the miraDry System. The permanent reduction of hair of all colors using miraWave is a significant technological advancement in the hair removal industry. Unlike laser hair removal systems, microwave energy doesn’t require a chromophore to be effective and therefore can be used on hair of all colors, including light colored hair, and is also not limited by an individual’s skin color.

“Based on the results we’ve seen using miraWave it’s clear that microwave energy has a role to play in the long term hair reduction space,” said Dr. Jeremy Brauer, Laser & Skin Surgery Center of New York. “Using this technology we’ve seen stable axillary hair reduction of approximately 70% regardless of color, and these results were based on a non-optimized treatment protocol. It will be exciting to see the increase in results given the protocol improvements we’ve made since then.”

With this clearance, the company has announced the introduction of the miraSmooth treatment. The launch of miraSmooth is a perfect addition to plastic surgery and dermatology practices looking to offer their patients the latest in aesthetic procedures. miraSmooth™ will be made available in select markets beginning August of 2015.

“I’m extremely excited about this significant advancement in hair removal and am just as pleased to announce that our center will begin to offer miraSmooth to patients,” added Dr. Grant Stevens, Medical Director of Marina Plastic Surgery. “With miraSmooth I can offer hair removal to patients that could not be treated with lasers before or for those that desire elimination of sweat along with their axillary hair. A premium procedure such as miraSmooth fits into our practice offerings nicely.”

About Miramar Labs:
Founded in 2006, Miramar Labs is a privately owned global medical device company dedicated to bringing the next generation energy modality to the field of dermatology. Supported by rigorous clinical research, Miramar Labs is focused on addressing aesthetic medical conditions for which there are significant unmet clinical needs. The company’s first priority is advancing aesthetic treatments using its proprietary miraWave technology. Physicians and patients are encouraged to visit www.miramarlabs.com for additional information about Miramar Labs.

Contact:
Elisabeth Barbaria
Sr. Marketing Manager Miramar Labs, Inc.
Ph: 408.579.8774
E: ebarbaria@miramarlabs.com

Miramar Labs® Announces Global Expansion of miraDry System into Chinese Market

SANTA CLARA, Calif., July 16, 2015. Global aesthetic company Miramar Labs, Inc., announced today that it has received State Food & Drug Administration (SFDA) approval for the marketing and sale of the miraDry system in the People’s Republic of China. The approval follows US Food and Drug Administration (FDA) clearance of miraDry in January 2011 and (CE) Mark approval in December 2013. The miraDry system utilizes the Company’s proprietary miraWave™ technology and is the first system to permanently eliminate apocrine and eccrine glands in the axilla which are the cause of unwanted sweat and odor.

“We are excited that miraDry has received marketing and sales approval for the Chinese market,” commented Mike Kleine, CEO and President of Miramar Labs. “This approval represents a significant opportunity in furthering our expansion in the Asian markets and fortifies our global leadership in the aesthetic market for sweat reduction.”

The miraDry system is currently distributed in over forty [40] countries worldwide. The company reports over 40,000 miraDry treatments have been performed, and sweat reduction is one of the fastest growing segments in aesthetics. With a population of over 1.4 billion people, expansion into China represents the largest growth opportunity for miraDry, as well as the aesthetic market, and the company is targeting very robust system sales in the first year alone.

About Miramar Labs:
Founded in 2006, Miramar Labs is a privately-owned global medical device company dedicated to bringing the next generation energy modality to the field of dermatology. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company’s first priority is the treatment of bothersome underarm sweat, an issue that millions of people deal with daily. Physicians and patients are encouraged to visit www.miramarlabs.com for additional information about Miramar Labs.

Contact:
Elisabeth Barbaria
Sr. Marketing Manager
Miramar Labs, Inc.
Ph: 408.579.8774
E: ebarbaria@miramarlabs.com

Miramar Labs® miraDry® System for the Elimination of Underarm Sweat and Odor to be the Subject of Four Clinical Presentations at ASLMS

SANTA CLARA, Calif., April 22, 2015. Global aesthetic company Miramar Labs has announced that its miraDry System will be featured as part of four clinical presentations at the American Society for Laser Medicine and Surgery’s annual meeting in Orlando, April 22-26. The company’s miraDry system, which utilizes Miramar’s proprietary miraWave™ technology, permanently eliminates apocrine and eccrine glands in the axilla which are the cause of unwanted sweat and odor. Technological hallmarks of the miraDry system include the bioTip patient interface and handpiece that optimally deliver electromagnetic energy to safely destroy the glands while utilizing hydro-ceramic cooling to ensure patient comfort and safety. ASLMS presenters will present results on efficacy and satisfaction data when using high volume anesthesia from prospective split study data, long-term efficacy and patient satisfaction, along with the latest in technological advancements demonstrating reduction in axillary hair of all colors achieved through the use of the miraDry system.

Friday, April 24 8:27 am – 8:37 am
Protocol and Nurse Practitioner’s Practice with Microwave Hyperhidrosis Treatment
Rebecca L. Sprague

Friday, April 24 4:05 pm – 4:11 pm
A Prospective, Randomized, Split Patient Study to Compare Two Methods of Anesthesia for Microwave Treatment of Excess Sweating
William Coleman (presenter), Patrick Coleman

Friday, April 24 4:12 pm – 4:18 pm
Long-Term Registry Follow-up From a Microwave-Based Treatment for Axillary Hyperhidrosis\
Carolyn Jacob (presenter), Steven Bloch, Suzanne Bruce, William Coleman, David Goldberg, Suzanne Kilmer, Michael Maris, Elizabeth Tanzi, David Vasily

Saturday, April 25 1:42 pm – 1:48 pm
Long-Term Follow-up Demonstrating Reduction of Axillary Hair Utilizing Microwave Technology
Brian Zelickson, Jeremy Brauer (presenter), David Vasily, Lori Brightman, Leonard Bernstein, Elliot Weill, Robert Anolik, Roy Geronemus

In addition to the four podium presentations, attendees will also have access to an additional poster sharing retrospective data highlighting miraDry’s effectiveness when used in conjunction with high volume anesthesia.

Retrospective Effectiveness Data in Use of High Volume Anesthesia with Microwave Device for Treatment of Axillary Sweat and Odor
Mark Taylor, Karen Stolman, Tony Chan

“I’m excited to present the results miraDry has on axillary hair,” said Jeremy Brauer, MD. “Not only will this provide an immediate additional benefit for anyone seeking the miraDry Procedure but, more importantly, shows the possibility for treating light and white colored hair. This is the first technology that is truly ‘color-blind’ when it comes to permanent hair reduction.”

“From Miramar Labs’ point of view, the future of aesthetics is about developing solutions for patients that want to improve not only themselves but their overall lifestyle, and the miraDry System is designed to provide physicians with the ability to deliver life-changing benefits for their patients,” said Michael Kleine, Miramar Labs President and Chief Executive Officer. “The clinical results and patient satisfaction achieved with miraDry have set new standards in aesthetics. And we fully expect to expand those standards as we develop new treatments using our microwave energy and the presentations at ASLMS are great examples of the future and groundbreaking treatments this technology holds for both clinicians and patients.”

About Miramar Labs: 
Founded in 2006, Miramar Labs is a privately owned global medical device company dedicated to bringing the next generation energy modality to the field of dermatology. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company’s first priority is the treatment of bothersome underarm sweat, an issue that millions of people deal with daily. Physicians and patients are encouraged to visit www.miramarlabs.com for additional information about Miramar Labs.

Contact
Elisabeth Barbaria
Sr. Marketing Manager Miramar Labs, Inc.
Ph: 408.579.8774
E: ebarbaria@miramarlabs.com

Breakthrough miraDry® Sweat Solution Appeals To Beauty Queen

Miss Tennessee 2014 Hayley Lewis Chooses Not to Sweat

SANTA CLARA, Calif., April 20, 2014 /PRNewswire-iReach/ — One in five Americans is bothered by underarm sweating and embarrassed by the wetness and odor that comes with it.1 However, most are not aware that there is now a long-lasting solution that has been clinically proven to stop sweat in its tracks. The miraDry procedure is the only FDA-cleared device that delivers energy non-invasively to the underarm area, creating localized heat to permanently eliminate sweat glands with dramatic improvement seen in as little as one treatment.
Reigning Miss Tennessee Hayley Lewis, like many others, has to consider sweat marks under her clothes, especially under the hot stage lights, with constant wardrobe changes, and the hectic schedule of Pageant life. Unaware of any viable solutions, Lewis learned about the innovative miraDry procedure on a visit to Changes Medical Spa in Boones Creek, TN. “It was exactly what I was hoping for; a safe, effective and permanent treatment to help control sweating. It was really amazing. I could see a difference almost immediately,” said Lewis. Since her treatment in January 2015, Lewis has seen a remarkable improvement.
According to Michael Kleine, Miramar Labs President and CEO, “Everyone sweats, but with miraDry, you can chose not to. While other therapies currently available offer only short term relief or are largely ineffective, this ground-breaking treatment represents a quantum leap for anyone dealing with sweat and odor.”
The non-invasive miraDry system from Miramar Labs®, Inc., a leading medical device manufacturer, delivers energy to the area under the arm where sweat glands reside, creating localized heat to destroy and eliminate those glands. Since sweat glands do not regenerate, the results are permanent.
Since its launch, the miraDry system has been used in over 30,000 treatments worldwide and currently boasts a 90% patient satisfaction rating, among the highest of all aesthetic procedures.2 miraDry is available globally.

For more information, visit the miraDry website at www.miraDry.com, or follow miraDry on Facebook/miraDry and Twitter @miraDry.

About Miramar Labs: 
Founded in 2006, Miramar Labs is a privately owned medical device company dedicated to bringing the next generation energy modality to the field of dermatology. Miramar Labs is the tenth company created by The Foundry, a leading medical device incubator based in Menlo Park, California. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company’s first priority is the treatment of excessive underarm sweat, a medical condition that significantly affects the quality of life of millions of people. Physicians and patients are encouraged to visit www.miraDry.com for additional information about Miramar Labs.

For more information, to arrange an interview with Hayley Lewis or to speak with a miraDry physician, contact: Melissa Ben-Yoseph, KelzPR
Melissa@kelzpr.com

1. Data on file
2. SOURCE Miramar Labs, Inc.

2-Year Study Results Point to Permanence

miraDry Long-term Results Point to Permanent Sweat Reduction

SANTA CLARA, Calif., Dec. 11, 2014 /PRNewswire/ — Miramar Labs®, Inc., a leading medical device manufacturer and maker of the miraDry® System, today announced the results of recently published 2-year data showing that miraDry efficacy observed at 30 days remains stable through 2 years.

The miraDry System delivers energy non-invasively to the area under the arm where sweat glands reside, creating localized heat to destroy and eliminate those glands. Since sweat glands do not regenerate, these results are expected to be permanent.

The study published in the journal Dermatologic Surgery reported1:

  • Greater than 90% efficacy
  • 70% reduction in the number of patients reporting problematic odor
  • Greater than 90% of patients had a dramatic improvement in quality of life based on DLQI score reduction
  • High patient satisfaction

Since its launch, the miraDry system has been used in over 30,000 treatments worldwide and currently boasts a 90% patient satisfaction rating in commercial use, among the highest of all aesthetic procedures.
“Since sweat and odor glands do not regenerate, these results are expected to be permanent,” commented Michael Kleine, Miramar Labs President and CEO. “This is a tremendous breakthrough, not only for excessive sweaters, but for anyone who manages nuisance sweat and odor.  Everyone sweats, but now, with miraDry, patients can choose not to.”

1. Lupin M. et. al. Dermatol Surg 2014; 40: 805-807

For more information, visit the miraDry website at www.miraDry.com, or follow miraDry on Facebook/miraDry and Twitter @miraDry.

About Miramar Labs: 
Founded in 2006, Miramar Labs is a privately owned medical device company dedicated to bringing the next generation energy modality to the field of dermatology. Miramar Labs is the tenth company created by The Foundry, a leading medical device incubator based in Menlo Park, California. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company’s first priority is the treatment of excessive underarm sweat, a medical condition that significantly affects the quality of life of millions of people. Physicians and patients are encouraged to visit www.miradry.com for additional information about Miramar Labs.

Contact
Donna Levy
Miramar Labs
408-579-8718

SOURCE Miramar Labs, Inc.